Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for budenofalk

  1. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Published
    20 December 2023
    View recommendations

    Sections for TA937